Latest

Jul 17, 2026, 18:44 Arvind Krishna Rebuilt IBM Around Software. Now He Has to Make the AI Stack Outrun the Mainframe Cycle

Jul 17, 2026, 16:45 Nikhil Kamath Turned Market Access Into a Media Platform. Influence Now Needs Clearer Boundaries

Jul 17, 2026, 13:40 Lucy Guo Built Passes Around Creator Ownership. Trust Must Become the Subscription Advantage

Jul 17, 2026, 10:35 Shashank Kumar Is Rewiring Razorpay Around Payment Success. Reliability Has to Pay

Jul 16, 2026, 16:45 Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit

Jul 16, 2026, 15:37 Nikesh Arora Made Palo Alto Networks Cybersecurity’s Consolidator. Now He Has to Make the Stack Work as One

Jul 16, 2026, 13:40 Gukesh Dommaraju Became Chess's Youngest World Champion. Defending the Crown Is a Different Business

Jul 16, 2026, 10:35 Scott Wu Joined Devin With Windsurf. The Combined Product Must Earn a US$26 Billion Valuation

BioNTech

Ugur Sahin, co-founder and chief executive of BioNTech

Ugur Sahin Has Given BioNTech a EUR16.8 Billion Runway. Six Cancer Readouts Must Now Set Its Direction

BioNTech retains EUR16.8 billion in cash and securities as it approaches six late-stage readouts. Ugur Sahin must convert scientific breadth into a focused cancer business.

Uğur Şahin, co-founder and Chief Executive Officer of BioNTech

Uğur Şahin Is Preparing to Leave BioNTech. The Oncology Pipeline Must Outlast Its Founder

BioNTech’s Covid success funded an ambitious oncology pipeline. With Uğur Şahin preparing to leave, clinical execution and succession have become inseparable.

Uğur Şahin, Chief Executive Officer and Co-Founder of BioNTech

Uğur Şahin’s US$11.1 Billion Pumitamig Alliance Now Faces the Phase III Arithmetic

Pumitamig has moved from BioNTech’s US$800 million Biotheus acquisition to an alliance worth up to US$11.1 billion. Uğur Şahin must show that encouraging lung-cancer signals survive global Phase III trials and a crowded competitive field.